Featuring market attractiveness scoring, total addressable market sizing, company benchmarking matrices, interactive Excel dashboards, deeper supply chain intelligence, emerging startup tracking, and granular product-level insights, The Business Research Company’s 2026 market reports are built to deliver research that is both more actionable and more strategically valuable.
Insulin biosimilars Market Revenue Growth On Track For A 14.4% CAGR Through 2030
The insulin biosimilars market has demonstrated substantial expansion in recent years. Its valuation is set to climb from $3.5 billion in 2025 to $4.02 billion in 2026, reflecting a compound annual growth rate (CAGR) of 14.8%. The observed growth during earlier periods can be attributed to the rising occurrence of diabetes, the high costs associated with originator insulin, heightened awareness regarding biosimilars, the expiration of patents for reference insulin products, and governmental initiatives aimed at promoting biosimilars.
The insulin biosimilars market size is anticipated to experience rapid expansion in the coming years, with projections indicating it will reach $6.89 billion in 2030, growing at a compound annual growth rate (CAGR) of 14.4%. This growth throughout the forecast period can be attributed to advancements in biosimilar production technologies, the expansion of healthcare infrastructure, supportive regulatory frameworks, the increasing adoption of telemedicine, and rising demand within emerging markets. Key trends expected during this period include a greater uptake of biosimilar insulins, the escalating global incidence of diabetes, the development of cost-effective diabetes management solutions, the proliferation of online and retail pharmacy channels, and an enhanced focus on patient-centric care.
Get A Free Sample Report With In-Depth Market Insights:
Insulin biosimilars Market Growth Factors Behind Sustained Expansion
The rising incidence of diabetes is anticipated to fuel the expansion of the insulin biosimilars market. Diabetes is defined as a collection of chronic metabolic conditions characterized by persistently high blood sugar levels. Biosimilars are crucial in diabetes treatment, presenting an alternative for insulin therapy, which in turn leads to increased demand for the insulin biosimilars market due to the growing prevalence of diabetes. For example, data from March 2024, released by the Office for Health Improvement and Disparities, a UK-based government department, shows that between March 2022 and March 2023, the percentage of individuals with type 1 diabetes who received all eight recommended care processes went up by 22%, and for type 2 diabetes, this figure increased by 21%. Furthermore, the percentage achieving target HbA1c levels reached 37.9%, marking the highest value ever reported by the National Diabetes Audit (NDA). Consequently, the growing prevalence of diabetes propels the insulin biosimilar market.
Insulin biosimilars Market Segments: Where Is Growth Concentrated?
The insulin biosimilars market covered in this report is segmented –
1) By Biosimilars Type: Rapid Acting biosimilars, Long Acting biosimilars, Premixed Acting biosimilars
2) By Disease Indication Type: Type I Diabetes, Type II Diabetes
3) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies
4) By End User: Hospitals, Ambulatory Surgical Centers, Other End Users
Subsegments:
1) By Rapid Acting Biosimilars: Insulin Aspart Biosimilars, Insulin Lispro Biosimilars, Insulin Glulisine Biosimilars
2) By Long Acting Biosimilars: Insulin Glargine Biosimilars, Insulin Detemir Biosimilars, Insulin Degludec Biosimilars
3) By Premixed Acting Biosimilars: Insulin Aspart Protamine Biosimilars, Insulin Lispro Protamine Biosimilars, Biphasic Insulin Biosimilars
Insulin biosimilars Market Industry Trends Fueling Future Revenue Growth
Key players within the insulin biosimilar market are forging partnerships to innovate new offerings and solidify their standing. These strategic collaborations involve companies leveraging each other’s strengths and resources to achieve shared benefits and success. For example, in September 2023, Meitheal Pharmaceuticals, Inc., a US-based pharmaceutical entity, entered a partnership with Tonghua Dongbao Pharmaceutical Co. Ltd., a China-based Active Pharmaceutical Ingredients (API) manufacturing company. This alliance is set to commercialize three insulin biosimilars, specifically insulin lispro, insulin glargine, and insulin aspart. Through this collaboration, Meitheal Pharmaceuticals intends to expand its product range and bolster its worldwide reach.
Insulin biosimilars Market Key Participants And Competitive Landscape
Major companies operating in the insulin biosimilars market are Eli Lilly and Company, Biocon Ltd., Mylan N.V., NOVO Nordisk A/S, Sanofi S.A, Sandoz International GmbH, Dr. Reddy’s Laboratories Ltd., Samsungbioepis Co. Ltd., Teva Pharmaceutical Industries Ltd., Stada Arzneimittel AG, Celltrion Inc., Fujifilm Kyowa Kirin Biologics Co. Ltd., Green Cross Corporation, Aurobindo Pharma Ltd., Intas Pharmaceuticals Ltd., Lupin Limited, Torrent Pharmaceuticals Ltd., Zydus Lifescience Ltd., Boehringer Ingelheim GmbH, Wockhardt Limited, Cadila Pharmaceuticals Ltd.
View The Full Insulin biosimilars Market Report:
Insulin biosimilars Market Geographic Landscape: Which Region Dominates Industry Growth?
North America was the largest region in the insulin biosimilars market in 2025. Asia-Pacific is expected to be the fastest-growing region in the global insulin biosimilars market report during the forecast period. The regions covered in the insulin biosimilars market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Reach Out To Our Team:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
